Nanopore sequencing systems generally use a protein pore in a planar lipid bilayer (PLB) suspended over a well (e.g., a cylindrical well) containing an electrolyte solution, which is also present in a much larger exterior reservoir (e.g., above the well). A working electrode and reference electrode are used to apply an electrical bias across the well and the exterior reservoir. The PLB extends over the well to both electrically and physically seal the well and separates the well from the larger exterior reservoir. When a lipid solvent mixture is first deposited into the cells to form the lipid bilayers, lipid bilayers are spontaneously formed in some of the cells, but in other cells there is merely a thick lipid membrane with multiple layers of lipid molecules combined with the solvent spanning across each of the wells of the cells. In order to increase the yield of the nanopore based sequencing chip (i.e., the percentage of cells in the nanopore based sequencing chip with properly formed lipid bilayers and nanopores), the nanopore based sequencing chip may perform additional steps to facilitate the formation of lipid bilayers in additional cells. Therefore, improved techniques for forming lipid bilayers in the cells of a nanopore based sequencing chip would be desirable.
Various embodiments of the invention are disclosed in the following detailed description and the accompanying drawings.
The invention can be implemented in numerous ways, including as a process; a device, an apparatus; a system; a composition of matter; a computer program product embodied on a computer readable storage medium; and/or a processor, such as a processor configured to execute instructions stored on and/or provided by a memory coupled to the processor. In this specification, these implementations, or any other form that the invention may take, may be referred to as techniques. In general, the order of the steps of disclosed processes may be altered within the scope of the invention. Unless stated otherwise, a component such as a processor or a memory described as being configured to perform a task may be implemented as a general component that is temporarily configured to perform the task at a given time or a specific component that is manufactured to perform the task. As used herein, the term ‘processor’ refers to one or more devices, circuits, and/or processing cores configured to process data, such as computer program instructions.
A detailed description of one or more embodiments of the invention is provided below along with accompanying figures that illustrate the principles of the invention. The invention is described in connection with such embodiments, but the invention is not limited to any embodiment. The scope of the invention is limited only by the claims and the invention encompasses numerous alternatives, modifications and equivalents. Numerous specific details are set forth in the following description in order to provide a thorough understanding of the invention. These details are provided for the purpose of example and the invention may be practiced according to the claims without some or all of these specific details. For the purpose of clarity, technical material that is known in the technical fields related to the invention has not been described in detail so that the invention is not unnecessarily obscured.
Nanopore membrane devices having pore sizes on the order of one nanometer in internal diameter have shown promise in rapid nucleotide sequencing. When a voltage potential is applied across a nanopore immersed in a conducting fluid, a small ion current attributed to the conduction of ions through the nanopore can be observed. The size of the current is sensitive to the pore size.
A nanopore based sequencing chip may be used for nucleic acid (e.g., DNA) sequencing. A nanopore based sequencing chip incorporates a large number of sensor cells configured as an array. For example, an array of one million cells may include 1000 rows by 1000 columns of cells.
With continued reference to
In some embodiments, a nanopore array enables parallel sequencing using the single molecule nanopore-based sequencing by synthesis (Nano-SBS) technique.
At stage A, a tagged nucleotide (one of four different types: A, T, G, or C) is not associated with the polymerase. At stage B, a tagged nucleotide is associated with the polymerase. At stage C, the polymerase is docked to the nanopore. The tag is pulled into the nanopore during docking by an electrical force, such as a force generated in the presence of an electric field generated by a voltage applied across the membrane and/or the nanopore.
Some of the associated tagged nucleotides are not base paired with the nucleic acid molecule. These non-paired nucleotides typically are rejected by the polymerase within a time scale that is shorter than the time scale for which correctly paired nucleotides remain associated with the polymerase. Since the non-paired nucleotides are only transiently associated with the polymerase, process 400 as shown in
Before the polymerase is docked to the nanopore, the conductance of the nanopore is ˜300 picosiemens (300 pS). At stage C, the conductance of the nanopore is about 60 pS, 80 pS, 100 pS, or 120 pS, corresponding to one of the four types of tagged nucleotides respectively. The polymerase undergoes an isomerization and a transphosphorylation reaction to incorporate the nucleotide into the growing nucleic acid molecule and release the tag molecule. In particular, as the tag is held in the nanopore, a unique conductance signal (e.g., see signal 210 in
In some cases, tagged nucleotides that are not incorporated into the growing nucleic acid molecule will also pass through the nanopore, as seen in stage F of
In one aspect, cell 500 also includes one or more hydrophobic layers. As shown in
In another aspect, well 505 (formed by the dielectric layer walls 504) further includes a volume of salt solution 506 above working electrode 502. In general, the methods of the present invention comprise the use of a solution (e.g., a salt solution, salt buffer solution, electrolyte, electrolyte solution, or bulk electrolyte) that comprises osmolytes. As used herein, the term “osmolyte” refers to any soluble compound that when dissolved into solution increases the osmolarity of that solution. In the present invention, an osmolyte is a compound that is soluble in solution within the architecture of a nanopore sequencing system, e.g., a well containing a salt solution or a bulk electrolyte as described herein. As such, the osmolytes of the present invention affect osmosis, particularly osmosis across a lipid bilayer. Osmolytes for use in the present invention include, without limitation, ionic salts such as lithium chloride (LiCl), sodium chloride (NaCl), potassium chloride (KCl), lithium glutamate, sodium glutamate, potassium glutamate, lithium acetate, sodium acetate, potassium acetate, calcium chloride (CaCl2), strontium chloride (SrCl2), manganese chloride (MnCl2), and magnesium chloride (MgCl2); polyols and sugars such as glycerol, erythritol, arabitol, sorbitol, mannitol, xylitol, mannisidomannitol, glycosyl glycerol, glucose, fructose, sucrose, trehalose, and isofluoroside; polymers such as dextrans, levans, and polyethylene glycol; and some amino acids and derivatives thereof such as glycine, alanine, alpha-alanine, arginine, proline, taurine, betaine, octopine, glutamate, sarcosine, y-aminobutyric acid, and trimethylamine N-oxide (“TMAO”) (see also e.g., Fisher et al. U.S. 20110053795, incorporated herein by reference in its entirety). In one embodiment, the present invention utilizes a solution comprising an osmolyte, wherein the osmolyte is an ionic salt. Those of ordinary skill in the art will appreciate other compounds that are suitable osmolytes for use in the present invention. In another aspect, the present invention provides solutions comprising two or more different osmolytes.
The architecture of the nanopore based sequencing chip described herein comprises an array of wells (e.g.,
As shown in
Cell 500 includes a counter electrode (CE) 510, which is in electrical contact with the bulk electrolyte 508. Cell 500 may optionally include a reference electrode 512. In some embodiments, counter electrode 510 is shared between a plurality of cells, and is therefore also referred to as a common electrode. The common electrode can be configured to apply a common potential to the bulk liquid in contact with the nanopores in the measurements cells. The common potential and the common electrode are common to all of the measurement cells.
In some embodiments, working electrode 502 is a metal electrode. For non-faradaic conduction, working electrode 502 may be made of metals that are resistant to corrosion and oxidation, e.g., platinum, gold, titanium nitride and graphite. For example, working electrode 502 may be a platinum electrode with electroplated platinum. In another example, working electrode 502 may be a titanium nitride (TiN) working electrode.
As shown in
For nucleic acid sequencing, a polymerase is attached to nanopore 516. A template of nucleic acid (e.g., DNA) is held by the polymerase. For example, the polymerase synthesizes DNA by incorporating hexaphosphate mono-nucleotides (HMN) from solution that are complementary to the template. A unique, polymeric tag is attached to each HMN. During incorporation, the tag threads the nanopore aided by an electric field gradient produced by the voltage between counter electrode 510 and working electrode 502. The tag partially blocks nanopore 516, procuring a measurable change in the ionic current through nanopore 516. In some embodiments, an alternating current (AC) bias or direct current (DC) voltage is applied between the electrodes.
The step of inserting a nanopore into a lipid bilayer is performed after it is determined that a lipid bilayer has been properly formed within a cell of the nanopore based sequencing chip. In some techniques, the process of determining whether a lipid bilayer has been properly formed in a cell may cause an already properly formed lipid bilayer to be destroyed. For example, a stimulus voltage may be applied to cause a current to flow across the electrodes. Although the measured response to the stimulus voltage may be used to distinguish between a cell with a properly formed lipid bilayer (i.e., a lipid bilayer that is two layers of lipid molecules thick) from a cell without a properly formed lipid bilayer (e.g., a cell with a thick lipid and solvent combined film that spans across the well of the cell), the stimulus voltage level is high enough to cause an already properly formed lipid bilayer to break down in some instances. In other words, the stimulus voltage for testing the lipid bilayer may be destructive to the lipid bilayer. In the event that an already properly formed lipid bilayer is destroyed by the stimulus voltage, a very high current begins to flow across the electrodes as a result of the short-circuit condition. In response, the system may try to reform a new lipid bilayer in the particular cell again; however, this is both time-consuming and inefficient. In addition, a lipid bilayer may not reform in the particular cell in a subsequent trial. As a result, the overall percentage of cells in the nanopore based sequencing chip with properly formed lipid bilayers and nanopores (i.e., the yield of the nanopore based sequencing chip) is reduced.
A non-destructive technique to detect a lipid bilayer formed in a cell of a nanopore based sequencing chip is disclosed. A non-destructive technique to detect a lipid bilayer has many advantages, including increasing the efficiency and yield of the nanopore based sequencing chip.
Electrical model 622 includes a capacitor 624 representing the electrical properties of working electrode 614. The capacitance associated with working electrode 614 is also referred to as a double layer capacitance (Cdouble layer). Electrical model 622 further includes a capacitor 626 (Cbilayer) that models a capacitance associated with the lipid membrane/bilayer and a resistor 628 (Rbilayer) that models a resistance associated with the lipid membrane/bilayer. The resistance associated with the lipid membrane/bilayer is very high, and therefore Rbilayer may be replaced by an open circuit, which reduces electrical model 622 to Cdouble layer in series with Cbilayer.
Voltage source Vliq 620 is an alternating current (AC) voltage source. Counter electrode 616 is immersed in the bulk liquid 618, and an AC non-Faradaic mode is utilized to modulate a square wave voltage Vliq and apply it to the bulk liquid in contact with the lipid membranes/bilayers in the measurement cells. In some embodiments, Vliq is a square wave with a magnitude of ±200-250 mV and a frequency between 25 and 100 Hz.
Pass device 606 is a switch that can be used to connect or disconnect the lipid membrane/bilayer and the electrodes from the measurement circuitry 600. The switch enables or disables a voltage stimulus that can be applied across the lipid membrane/bilayer in the cell. Before lipids are deposited to the cell to form a lipid bilayer, the impedance between the two electrodes is very low because the well of the cell is not sealed, and therefore switch 606 is kept open to avoid a short-circuit condition. Switch 606 may be closed once lipid solvent has been deposited to the cell that seals the well of the cell.
Circuitry 600 further includes an on-chip fabricated integrating capacitor 608 (ncap). Integrating capacitor 608 is pre-charged by using a reset signal 603 to close switch 601, such that integrating capacitor 608 is connected to a voltage source Vpre 605. In some embodiments, voltage source Vpre 605 provides a constant positive voltage with a magnitude of 900 mV. When switch 601 is closed, integrating capacitor 608 is pre-charged to the positive voltage level of voltage source Vpre 605.
After integrating capacitor 608 is pre-charged, reset signal 603 is used to open switch 601 such that integrating capacitor 608 is disconnected from voltage source Vpre 605. At this point, depending on the level of Vliq, the potential of counter electrode 616 may be at a higher level than the potential of working electrode 614, or vice versa. For example, during the positive phase of square wave Vliq (i.e., the dark period of the AC voltage source signal cycle), the potential of counter electrode 616 is at a higher level than the potential of working electrode 614. Similarly, during the negative phase of square wave Vliq (i.e., the bright period of the AC voltage source signal cycle), the potential of counter electrode 616 is at a lower level than the potential of working electrode 614. Due to this potential difference, integrating capacitor 608 may be charged during the dark period of the AC voltage source signal cycle and discharged during the bright period of the AC voltage source signal cycle.
Depending on the sampling rate of an analog-to-digital converter (ADC) 610, integrating capacitor 608 charges or discharges for a fixed period of time, and then the voltage stored in integrating capacitor 608 may be read out by ADC 610. After the sampling by ADC 610, integrating capacitor 608 is pre-charged again by using reset signal 603 to close switch 601, such that integrating capacitor 608 is connected to voltage source Vpre 605 again. In some embodiments, the sampling rate of ADC 610 is between 1500 to 2000 Hz. In some embodiments, the sampling rate of ADC 610 is up to 5 kHz. For example, with a sampling rate of 1 kHz, integrating capacitor 608 charges or discharges for a period of ˜1 ms, and then the voltage stored in integrating capacitor 608 is read out by ADC 610. After the sampling by ADC 610, integrating capacitor 608 is pre-charged again by using reset signal 603 to close switch 601 such that integrating capacitor 608 is connected to voltage source Vpre 605 again. The steps of pre-charging the integrating capacitor 608, waiting a fixed period of time for the integrating capacitor 608 to charge or discharge, and sampling the voltage stored in integrating capacitor by ADC 610 are then repeated in cycles throughout a lipid bilayer measurement phase of the system.
Circuitry 600 may be used to detect whether a lipid bilayer is formed in the cell by monitoring a delta voltage change, ΔVADC, at integrating capacitor 608 (ncap) in response to a delta voltage change (ΔVliq) applied to the bulk liquid in contact with the lipid membrane/bilayer. As will be described in greater detail below, during the lipid bilayer measurement phase, circuitry 600 may be modeled as a voltage divider with Cbilayer 626, Cdouble layer 624, and ncap 608 connected in series, and a voltage change tapped at an intermediate point of the voltage divider can be read by ADC 610 for determining whether a lipid bilayer has been formed.
When operating in an AC mode, the voltage read by the ADC (VADC) can be determined by:
The AC impedance of the double layer, Z(double layer), has a very low value compared to Z(bilayer) and Z(ncap) because Cdouble layer is much larger than Cbilayer or the capacitance of ncap. Therefore, substituting Z(ncap)=1/(jωCncap), Z (bilayer)=1/jωCbilayer, and Z(double layer)=0, equation (1) can be simplified as:
When lipids are first deposited into the cells to form the lipid bilayers, some of the cells have lipid bilayers spontaneously formed, but some of the cells merely have a thick lipid membrane (with multiple layers of lipid molecules and solvent combined together) spanning across each of the wells of the cells. The capacitance associated with a lipid bilayer is larger than the capacitance associated with a lipid membrane that is more than two layers of lipid molecules thick because the capacitance of the lipid membrane/bilayer is inversely proportional to its thickness. As a lipid membrane thins out and transitions to become a lipid bilayer, the thickness decreases and its associated capacitance increases. In Equation (2) above, as a lipid bilayer begins to form within a cell, C(bilayer) increases while C(ncap) remains constant, such that on the whole VADC increases. An increase in VADC can therefore be used as an indicator that a lipid bilayer has been formed within a cell.
In some embodiments, a delta voltage change ΔVADC at integrating capacitor 608 (ncap) in response to a delta voltage change (ΔVliq) applied to the bulk liquid in contact with the lipid membrane/bilayer is monitored in order to detect whether a lipid bilayer has been formed in a cell. For example, Equation (2) may be rewritten as:
In Equation (3) above, because C(ncap) remains constant, while C(bilayer) increases as a lipid bilayer begins to form within a cell, ΔVADC increases as well. ΔVADC is roughly proportional to the capacitance associated with the lipid membrane/bilayer, C(bilayer). An increase in ΔVADC can therefore be used as an indicator that a lipid bilayer has been formed within a cell.
In some embodiments, in order to maximize the observable ΔVADC for a more reliable detection of a lipid bilayer, ΔVADC in response to a maximum voltage change applied to the bulk liquid in contact with the lipid membrane/bilayer (max ΔVliq) is monitored in order to detect whether a lipid bilayer has been formed in a cell.
In
In
In some embodiments, the absolute value of ΔVADC (|ΔVADC|) observed when the absolute value of ΔVliq (|ΔVliq|) is at a maximum is compared with a predetermined threshold. If (|ΔVADC|>predetermined threshold), then it is determined that a lipid bilayer is detected. Conversely, if (|ΔVADC|<predetermined threshold), then it is determined that a lipid bilayer is not detected.
When a lipid solvent mixture is first deposited into the cells to form the lipid bilayers, lipid bilayers are spontaneously formed in some of the cells, but in other cells there is merely a thick lipid membrane with multiple layers of lipid molecules combined with the solvent spanning across each of the wells of the cells. In order to increase the yield of the nanopore based sequencing chip (i.e., the percentage of cells in the nanopore based sequencing chip with properly formed lipid bilayers and nanopores), the nanopore based sequencing chip may perform additional steps to facilitate the formation of lipid bilayers in additional cells. Therefore, improved techniques for forming lipid bilayers in the cells of a nanopore based sequencing chip would be desirable.
In the present application, improved techniques of forming lipid bilayers in the cells of a nanopore based sequencing chip for analyzing molecules are disclosed. One of the improved techniques applies one or more lipid bilayer initiating stimuli. Different types of lipid bilayer initiating stimuli may be applied, as will be described in greater detail below. For example, mechanical, electrical, or physical stimuli may be applied. Those of ordinary skill in the art will appreciate that other types of stimuli may be suitable for use with the present invention. One or more types of lipid bilayer initiating stimuli may be applied simultaneously, or in different order. The one or more types of lipid bilayer initiating stimuli may be applied in a process that repeats a plurality of time.
A lipid bilayer initiating stimulus facilitates the creation of a small lipid bilayer on a thick lipid membrane. Once a small transient lipid bilayer on a thick lipid membrane is formed, the application of additional lipid bilayer initiating stimuli acts as a positive feedback to continue to enlarge the surface area of the lipid bilayer. As a result, the time required to form lipid bilayers in the cells of the nanopore based sequencing chip can be significantly reduced.
One type of lipid bilayer initiating stimulus is a mechanical stimulus, such as a vibration stimulus. Mechanical vibrations of a thick lipid membrane will cause the lipid molecules to rearrange and move around each other, thereby promoting the self-assembly of some lipid molecules into a two-layered sheet, with the tails pointing towards the center of the sheet to form a small area of lipid bilayer. In some embodiments, vibration of the lipid membrane may be introduced by generating waves in the bulk electrolyte (see bulk electrolyte 114 in
Another type of lipid bilayer initiating stimulus is an electrical stimulus. Applying an electrical lipid bilayer initiating stimulus to the cells that have not had lipid bilayers formed therein yet can improve the efficiency of liquid flow above the thick lipid membranes, thereby facilitating the removal of any excess lipid solvent such that the thick lipid membranes can be thinned out and transitioned into lipid bilayers more efficiently. Applying the electrical lipid bilayer initiating stimulus to the cells that have not had lipid bilayers formed therein yet will also create electrostatic forces that tend to squeeze out the excess lipid solvent and thin out the thick lipid membranes into lipid bilayers. On the other hand, the cells that have already had lipid bilayers properly formed therein should not be further exposed to the same electrical lipid bilayer initiating stimulus, as the electrical stimulus may cause some of the thin lipid bilayers to break down. Therefore, it is advantageous to use the non-destructive technique described in the present application to detect and separate the portion of the cells in the nanopore based sequencing chip that have lipid bilayers formed therein from the portion of the cells that do not have lipid bilayer properly formed therein yet. By dividing the cells into different groups, the cells in different groups can be processed differently, thereby achieving greater efficiency and increasing the overall yield of the nanopore based sequencing chip.
Another type of lipid bilayer initiating stimulus is a physical stimulus. For example, flowing a salt/electrolyte buffer solution through the cells of the nanopore based sequencing chip via a flow chamber facilitates the formation of a lipid bilayer over each of the cells. The salt buffer solution flowed over the cells facilitates the removal of any excess lipid solvent such that the thick lipid membranes can be thinned out and transitioned into lipid bilayers more efficiently. In some embodiments, a salt buffer solution is flowed for a period of two seconds. However, other predetermined period of time may be used as well. The buffer solution flowing cycle may be repeated a number of times. However, it has been found that the number of buffer solution flowing cycles needed to obtain a satisfactory yield of the nanopore based sequencing chip may be as high as tens or hundreds of cycles.
One of the improved techniques applies a salt/electrolyte buffer solution flow over the lipid membrane with a lower osmolarity/osmotic concentration than the osmolarity of the salt buffer solution below the lipid membrane in order to introduce an osmotic imbalance between the salt buffer solution above and below the lipid membrane, which causes the lipid solvent membrane to bow upwards. With the lipid membrane pushed outward from the well, a greater contact surface area of the lipid membrane is exposed to the flow of the salt buffer solution and, as a result, the flow of the salt buffer solution can more effectively remove any excess lipid solvent, such that the thick lipid membrane can be thinned out and transitioned into a lipid bilayer more efficiently. This technique has many advantages, including reducing the time to form lipid bilayers and increasing the efficiency and yield of the nanopore based sequencing chip.
Process 1100 includes steps in which different types of fluids (e.g., liquids or gases) are flowed through the cells of the nanopore based sequencing chip via a flow chamber. Multiple fluids with significantly different properties (e.g., compressibility, hydrophobicity, and viscosity) are flowed over an array of sensors on the surface of the nanopore based sequencing chip. For improved efficiency, each of the sensors in the array should be exposed to the fluids in a consistent manner. For example, each of the different types of fluids should be flowed over the nanopore based sequencing chip such that the fluid may be delivered to the chip, evenly coating and contacting each of the cells' surfaces, and then delivered out of the chip. As described above, a nanopore based sequencing chip incorporates a large number of sensor cells configured as an array. As the nanopore based sequencing chip is scaled to include more and more cells, achieving an even flow of the different types of fluids across the cells of the chip becomes more challenging.
In some embodiments, the nanopore based sequencing system that performs process 1100 of
With reference to
System 1200 allows the fluids to flow more evenly on top of all the sensors on the chip surface. The channel width is configured to be narrow enough such that capillary action has an effect. More particularly, the surface tension (which is caused by cohesion within the fluid) and adhesive forces between the fluid and the enclosing surfaces act to hold the fluid together, thereby preventing the fluid or the air bubbles from breaking up and creating dead zones. For example, the channel may have a width of 1 millimeter or less. The narrow channel enables controlled flow of the fluids and minimizes the amount of remnants from a previous flow of fluids or gases.
With reference to
At 1104, a lipid and solvent mixture is flowed through the cells of the nanopore based sequencing chip via the flow chamber. In some embodiments, the lipid and solvent mixture includes lipid molecules such as diphytanoylphosphatidylcholine or 1,2-diphytanoyl-sn-glycero-3-phosphocholine (DPhPC), and 1,2-di-O-phytanyl-sn-glycero-3-phosphocholine (DOPhPC). In some embodiments, the lipid and solvent mixture includes decane or tridecane. When the lipid and solvent mixture is first deposited into the cells to form the lipid bilayers, some of the cells have lipid bilayers spontaneously formed, but some of the cells merely have a thick lipid membrane (with multiple layers of lipid molecules and solvent combined together) spanning across each of the wells of the cells.
At 1106, a salt/electrolyte buffer solution is flowed through the cells of the nanopore based sequencing chip via the flow chamber to substantially fill the external reservoir with the salt buffer solution.
At 1108, in order to increase the yield of the nanopore based sequencing chip (i.e., the percentage of cells in the nanopore based sequencing chip with properly formed lipid bilayers and nanopores), the nanopore based sequencing chip may apply one or more types of lipid bilayer initiating stimuli to facilitate the formation of lipid bilayers in additional cells. As described above, one or more types of lipid bilayer initiating stimuli may be applied simultaneously, or in different orders, during a lipid bilayer initiating stimulus phase (step 1108), which may be repeated (determined by step 1110) a plurality of times.
At 1304, the non-destructive technique described in the present application is used to detect whether a lipid bilayer is formed in a cell using circuitry 600 of
At 1306, it is determined whether the mechanical stimulus phase should be repeated. Different criteria may be used at this step. In some embodiments, the mechanical stimulus phase is performed a predetermined number of times. In some embodiments, the mechanical stimulus phase is repeated until a target yield for the nanopore based sequencing chip has been reached. In some embodiments, if the incremental number or percentage of cells that have just been detected as having lipid bilayers formed during the last round of thinning by the stimulus is lower than a predetermined threshold, then process 1300 is terminated.
Process 1300 proceeds to step 1308 if the mechanical stimulus phase is going to be repeated next. At step 1308, the next mechanical stimulus level to be applied is determined. In some embodiments, the mechanical stimulus level is increased by a fixed predetermined amount. In some embodiments, if the incremental number or percentage of cells that have just been detected as having lipid bilayers formed during the last iteration is lower than a predetermined threshold, then the mechanical stimulus level is increased by a fixed predetermined amount; otherwise, the previous mechanical stimulus is found to be effective and thus the same mechanical stimulus level is used again. Process 1300 then proceeds to 1302 and the process is repeated.
At 1404, the non-destructive technique described in the present application is used to detect whether a lipid bilayer is formed in a cell using circuitry 600 of
At 1406, it is determined whether the electrical stimulus phase should be repeated. Different criteria may be used at this step. In some embodiments, the electrical stimulus phase is performed a predetermined number of times. In some embodiments, the electrical stimulus phase is repeated until a target yield for the nanopore based sequencing chip has been reached. In some embodiments, if the incremental number or percentage of cells that have just been detected as having lipid bilayers formed during the last round of thinning by the stimulus is lower than a predetermined threshold, then process 1400 is terminated.
Process 1400 proceeds to step 1408 if the electrical stimulus phase is going to be repeated next. At step 1408, the next electrical stimulus level to be applied is determined. In some embodiments, the electrical stimulus level is increased by a fixed predetermined amount. In some embodiments, if the incremental number or percentage of cells that have just been detected as having lipid bilayers formed during the last iteration is lower than a predetermined threshold, then the electrical stimulus level is increased by a fixed predetermined amount; otherwise, the previous electrical stimulus is found to be effective and thus the same electrical stimulus level is used again. Process 1400 then proceeds to 1402 and the process is repeated.
For example, the salt electrolyte buffer solution that is flowed through the cells of the nanopore based sequencing chip via the flow chamber at step 1502 has a lower concentration (e.g., 500 mM) than the electrolyte solution that is present in the well (e.g., 2 M), creating a osmolarity difference of 1.5 M. In response to the lower concentration electrolyte solution flowing in the external reservoir (i.e., on the cis side of the lipid membrane), water diffuses across the lipid membrane from the reservoir into the well in order to equalize the concentration on the cis and trans sides of the lipid membrane. This equalization takes place almost instantaneously, since the water molecules readily flow through the lipid membrane. The concentrations on both sides of the lipid membrane equalize to that of the cis side (e.g., 500 mM) since the volume of the external reservoir is significantly greater than that of the trans side (the well). This effectively increases the volume of water under the lipid membrane in the well, causing the lipid membrane to bow upwards, as shown in
As shown above, since water may diffuse across the lipid membranes and the salt electrolyte buffer solution that is flowed through the cells may introduce different osmolytes into the external reservoir over time, both the volume and the osmolyte content of the liquid held in the external reservoir and the wells may change over time. It is recognized that the external reservoir may be characterized by a first reservoir osmolarity, which is the osmolarity of the liquid contained in the external reservoir at a specific time. A well in a cell may also be characterized by a second reservoir osmolarity, which is the osmolarity of the liquid contained in the well and confined by the lipid bilayer at a specific time.
At 1504, the non-destructive technique described in the present application is used to detect whether a lipid bilayer is formed in a cell using circuitry 600 of
At 1506, it is determined whether the salt buffer solution flowing phase should be repeated. Different criteria may be used at this step. In some embodiments, the salt buffer solution flowing phase is performed a predetermined number of times. In some embodiments, the phase is repeated until a target yield for the nanopore based sequencing chip has been reached. In some embodiments, if the incremental number or percentage of cells that have just been detected as having lipid bilayers formed during the last round of thinning by the buffer solution flow is lower than a predetermined threshold, then process 1500 is terminated.
Process 1500 proceeds to step 1508 if the salt buffer solution flowing phase of process 1500 is going to be repeated next. At step 1508, the next salt buffer solution concentration to be applied is determined. For example, the concentration of the salt buffer solution may be progressively increased from the concentration used in the last iteration of step 1502. The concentration of the salt buffer solution is progressively increased because as the salt buffer solution flowing phase is repeated a number of times, more and more lipid bilayers are formed and a smaller difference of concentration between the electrolyte solution above and below the lipid membrane will ensure that the lipid bilayers are not burst by the excess water forced into the wells. Process 1500 then proceeds to 1502 and the process is repeated.
For each of the figures, the x-axis is the voltage change at integrating capacitor 608 (ncap), ΔVADC, in response to a voltage change (ΔVliq) applied to the bulk liquid in contact with the lipid membrane/bilayer, while the y-axis is the number of cells with its ΔVADC value within certain ΔVADC bins. In this example, cells that have a ΔVADC value of 50 or above are determined as having lipid bilayers formed therein. Comparing
This application is a continuation of U.S. patent application Ser. No. 16/219,464, filed Dec. 13, 2018, which is continuation of International Application No. PCT/EP2017/065626, filed Jun. 26, 2017, which claims priority to U.S. Provisional Application No. 62/355,140, filed Jun. 27, 2016, each of which is herein incorporated by reference in its entirety.
Number | Date | Country | |
---|---|---|---|
62355140 | Jun 2016 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16219464 | Dec 2018 | US |
Child | 18658103 | US | |
Parent | PCT/EP2017/065626 | Jun 2017 | WO |
Child | 16219464 | US |